Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, phase II/III trial on acetyl-L-carnitine in ALS
2023-509853-29-00Phase 3Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Acetyl-L-carnitine (Nicetile) + riluzole with Placebo + riluzole (2 arms). Primary endpoint: Self-sufficiency at 48 weeks. Planned start Feb 2025; status: authorised.
02
Drugs
acetyl-l-carnitine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2023-509853-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509853-29-00.